|
|
News Breaks | | | | February 13, 2013 | | 09:30 EDT |  | MDVN | Medivation says 93% of patients in study had PSA decrease
Medivation and Astellas Pharma announced that data for enzalutamide, an oral androgen receptor inhibitor, will be presented at the American Society of Clinical Oncology 2013 Genitourinary Cancers Symposium in Orlando, Florida. In one presentation, titled "Enzalutamide monotherapy: Phase 2 study results in hormone-naïve prostate cancer patients," it will be noted that the phase 2 study assessed the efficacy and safety of enzalutamide monotherapy in 67 patients who had never received hormone therapy and presented with normal testosterone levels. The analysis showed ninety-three percent of study participants experienced a ≥80% PSA decrease at week 25. Also, median change in PSA was -99.6%. | |
|
News For MDVN From The Last 14 Days Check below for free stories on MDVN the last two weeks. |
|
|
| May 14, 2013 | | 14:59 EDT |  | MDVN | Medivation has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov host a conference call with CEO David Hung on May 16 at 10 am. | | | May 9, 2013 | | 16:23 EDT |  | MDVN | Medivation sees FY13 operating expenses, net of Astellas payments, $285M-$300M
 Subscribe for More Information | | | 16:23 EDT | | MDVN | Medivation reports Q1 EPS (36c), consensus (41c)
Reports Q1 revenue $46.15M, consensus $38.54M. | | | 15:27 EDT | | MDVN | Notable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include priceline.com (PCLN), consensus $5.27; Public Storage (PSA), consensus $1.62; NVIDIA (NVDA), consensus 10c; CareFusion (CFN), consensus 53c; Assured Guaranty (AGO), consensus 68c; Medivation (MDVN), consensus (41c); Great Plains Energy (GXP), consensus 12c; Salix Pharmaceuticals (SLXP), consensus 68c; Air Lease (AL), consensus 38c; Sotheby's (BID), consensus (12c). | |
|
|
|
|
|
|
